Gene Delivery Vectors Research Articles

Enhancing non-viral DNA delivery systems: Recent advances in improving efficiency and target specificity.

DNA-based therapies are often limited by challenges such as stability, long-term integration, low transfection efficiency, and insufficient targeted DNA delivery. This review focuses on recent progress in the design of non-viral delivery systems for enhancing targeted DNA delivery and modulation of therapeutic efficiency. Cellular uptake and intracellular trafficking mechanisms play a crucial role in optimizing gene delivery efficiency. There are two main strategies employed to improve the efficiency of gene delivery vectors: (i) explore different administration routes (e.g., mucosal, intravenous, intramuscular, subcutaneous, intradermal, intratumoural, and intraocular) that best facilitates optimal uptake into the targeted cells and organs and (ii) modify the delivery vectors with cell-specific ligands (e.g., natural ligands, antibodies, peptides, carbohydrates, or aptamers) that enable targeted uptake to specific cells with higher specificity and improved biodistribution. We describe how recent progress in employing these DNA delivery strategies is advancing the field and increasing the clinical translation and ultimate clinical application of DNA therapies.

Metabolic engineering improves transduction efficiency and downstream vector isolation by altering the lipid composition of extracellular vesicle-enclosed AAV.

Adeno-associated viruses (AAV) are promising vectors for gene therapy due to their efficacy in vivo. However, there is room for improvement to address key limitations such as the pre-existing immunity to AAV in patients, high-dose toxicity, and relatively low efficiency for some cell types. This study introduces a metabolic engineering approach, using knockout of the enzyme phosphatidylserine synthase 1 (PTDSS1) to increase the abundance of extracellular vesicle-enclosed AAV (EV-AAV) relative to free AAV in the supernatant of producer cells, simplifying downstream purification processes. The lipid-engineered HEK293T-ΔPTDSS1 cell line achieved a 42.7-fold enrichment of EV-AAV9 compared to free AAV9 in the supernatant. The rational genetic strategy also led to a 300-fold decrease of free AAV in supernatant compared to wild-type HEK293T. The membrane-engineered EV-AAV9 (mEV-AAV9) showed unique envelope composition alterations, including cholesterol enrichment and improved transduction efficiency in human AC16 cardiomyocytes by 1.5-fold compared to conventional EV-AAV9 and by 11-fold compared to non-enveloped AAV9. Robust in-vivo transduction four weeks after intraparenchymal administration of mEV-AAV9 was observed in the murine brain. This study shows promise in the potential of lipid metabolic engineering strategies to improve the efficiency and process development of enveloped gene delivery vectors.

Fine-Tuned "Click" Functionalization of PAMAM Dendrimers with a Linear Fluorinated Guanidino Linker: Synthesis, Characterization, and Applications.

This study presents the synthesis, characterization, and application of multifunctional PAMAM G2 and G4 dendrimers decorated with a linear fluorinated guanidino linker designed to improve gene delivery efficiency while minimizing cytotoxicity. For the first time, we were able to fine-tune the degree of grafting (DG) during the functionalization process through efficient "click" Michael addition, achieving the synthesis of a collection of six PAMAM conjugates that showed a significant enhancement in transfection efficiency (TE), surpassing the performance of traditional nonviral vectors. The incorporation of fluorinated moieties not only facilitated better deoxyribonucleic acid (DNA) condensation and TE but also introduced potential applications in 19F magnetic resonance imaging thanks to the sharp and intense fluorine nuclear magnetic resonance signals and favorable relaxation parameters. The new dendrimer conjugates demonstrated a promising balance between low cytotoxicity and high TE, with the low-generation PAMAM G2 with lower DG being the best-performing conjugate, making them strong candidates for further development in gene therapy. These findings highlight the potential of these multifunctional PAMAM dendrimers as efficient, nontoxic, and trackable gene delivery vectors.

Engineering an Ultrasound-Responsive Glycopolymersome for Hepatocyte-Specific Gene Delivery.

The ability to design liver-targeted gene delivery vectors is plagued with difficulties ranging from carrier-mediated cellular toxicity to challenges in encapsulating sensitive nucleic acids. Herein, we present an ultrasound-responsive glycopolymersome strategy for in situ loading of nucleic acids and achieving hepatocyte-specific gene delivery. This glycopolymersome is self-assembled from a block copolymer, N-acetylgalactosamine-grafted poly(glutamic acid)-block-poly(ε-caprolactone) (PGAGalNAc-b-PCL). GalNAc is introduced to afford liver targeting through the selective binding to the asialoglycoprotein receptor overexpressed on hepatocytes. External ultrasound is utilized to assist in encapsulating nucleic acids within the hydrophilic lumen of glycopolymersomes by exploiting their ultrasound responsiveness nature. Biological studies confirmed the successful encapsulation of plasmid DNA (pDNA) and small interfering RNA (siRNA), rapid nuclear internalization, and efficient gene transfection. These findings collectively demonstrated that this ultrasound-responsive glycopolymersome could be exploited as a novel safe and efficient gene vector targeting hepatocytes.

Sonogenetics in the Treatment of Chronic Diseases: A New Method for Cell Regulation.

Sonogenetics is an innovative technology that integrates ultrasound with genetic editing to precisely modulate cellular activities in a non-invasive manner. This method entails introducing and activating mechanosensitive channels on the cell membrane of specific cells using gene delivery vectors. When exposed to ultrasound, these channels can be manipulated to open or close, thereby impacting cellular functions. Sonogenetics is currently being used extensively in the treatment of various chronic diseases, including Parkinson's disease, vision restoration, and cancer therapy. This paper provides a comprehensive review of key components of sonogenetics and focuses on evaluating its prospects and potential challenges in the treatment of chronic disease.

Applications and Developments of Gene Therapy Drug Delivery Systems for Neurological Disorders

AbstractNeurological diseases (NDs) such as Alzheimer's disease, Parkinson's disease, ischemic strokes, spinal cord injuries, and other similar conditions that continue to pose a substantial health and economic burden on a global scale. It is crucial to tackle the difficulties provided by current medications due to the adverse effects and its immunological reactions to develop improved treatments for neurodegenerative illnesses. Gene therapy is currently being extensively used in preclinical and clinical studies for various diseases because of its ability to enhance the delivery and effectiveness of treatments. Various gene delivery techniques, including messenger RNA, small interfering RNA, antisense oligonucleotides, microRNA, CRISPR/Cas9 system, and plasmid DNA, have been created to address these difficulties. The goal of this study is to provide a clear overview of the pathophysiological underpinnings of NDs illnesses while also illuminating recent developments in gene delivery vector technologies. It goes over the main classifications of these vectors, their individual benefits and drawbacks, and their specific applications in the delivery of gene therapy.

Development and Evaluation of a Novel Biodegradable Poly(amidoamine) with Bis(guanidinium) and Benzene Ring Structures for Enhanced Gene Delivery

Cationic polymer carriers have shown promise in non-viral gene delivery but face challenges such as low transfection efficiency and high toxicity. To address these issues, we synthesized a novel biodegradable poly(amidoamine) (PAA) cationic polymer, 4-(4-biguanide benzoylamino)butylamine-N,N’-bis(acryloyl)cystamine (PDAB-CBA). This polymer incorporates bis(guanidinium) groups and a hydrophobic benzene ring to enhance membrane affinity and hydrophobic interactions, respectively, thereby improving gene delivery performance. The inclusion of disulfide bonds in the polymer’s backbone imparts reductive response properties, allowing for degradation into small molecular weight fragments within cellular environments and reducing cytotoxicity. Our studies demonstrated that PDAB-CBA formed stable, uniform nanoparticles with plasmid DNA (pDNA), achieving an encapsulation efficiency of approximately 85% at a 6:1 weight ratio. The polyplexes had the average particle size of around 100 nm and the zeta potential between 25-35 mV, ensuring effective cellular uptake. PDAB-CBA/pDNA polyplexes exhibited higher transfection efficiency, with relative light units (RLU) greater than 1 × 105 at weight ratios of 6:1 to 24:1, compared to PEI/pDNA. Furthermore, PDAB-CBA demonstrated low cytotoxicity, maintaining cell viability above 80% at weight ratios below 24:1, and effectively protected genes against DNaseI degradation and heparin replacement. The primary endocytosis pathway for these polyplexes was clathrin-mediated endocytosis. Overall, PDAB-CBA exhibited superior gene delivery capabilities and a favorable safety profile, providing a new strategy for the design of efficient and low-toxicity gene delivery vectors.

FastAd: A versatile toolkit for rapid generation of single adenoviruses or diverse adenoviral vector libraries

Adenoviruses (Ads) are potent gene delivery vectors for in vitro and in vivo applications. However, current methods for their construction are time-consuming and inefficient, limiting their rapid production and utility in generating complex genetic libraries. Here, we introduce FastAd, a rapid and easy-to-use technology for inserting recombinant “donor” DNA directly into infectious “receiver” Ads in mammalian cells by the concerted action of two efficient recombinases: Cre and Bxb1. Subsequently, the resulting mixed recombinant Ad population is subjected to negative selections by flippase (FLP) recombinase to remove viruses that missed the initial recombination. With this approach, recombinant Ad production time is reduced from two months to 10 days or less. FastAd can be applied for inserting complex genetic DNA libraries into Ad genomes, as evidenced by the generation of barcode libraries with over 3 million unique clones from a T25 flask-scale of transfection. Furthermore, we leveraged FastAd to construct an Ad library containing a comprehensive genome-wide CRISPR/Cas9 guide RNA (gRNA) library and demonstrated its effectiveness in uncovering novel virus-host interactions. In summary, FastAd enables the rapid generation of single Ad vectors or complex genetic libraries, facilitating not only novel applications of Ad vectors but also research in foundational Ad biology.

The Microbial Sources of Bioactive Compounds: Potential Anticancer Therapeutic Options

Chemotherapy and other traditional anticancer treatments are losing their efficacy in the battle against cancer. As a result, cancer treatment strategies must be continually adjusted to meet the rising demand for alternative medicines. Several viral and non-viral vectors have been used previously. However, it has been shown that microorganisms are a strong contender for successfully combating cancer. They are a remarkable source of toxins, polysaccharides, tumor-specific anticancer genes, nanodrugs and gene-delivery vectors. One of the emerging key players in cancer therapy is bacteria. It has been demonstrated that traditional methods of altering the microbiome, such as antibiotics, probiotics and microbiota transplants, can sometimes increase the effectiveness of cancer therapies. However, problems with these methods, such as consistency and collateral damage to the commensal microbiota, spur the development of new technologies specifically aimed at the microbiome-cancer interface. In light of nanotechnology’s success in transforming cancer diagnostics and treatment, nanotechnologies with the capacity to control interactions that occur across microscopic and molecular length scales in the microbiome and the tumor microenvironment have the potential to provide innovative methods for cancer treatment. The relationship between nanotechnology, the microbiome and cancer offers tremendous potential. This paper highlights the contributions of significant bacterial groups to several anticancer research fields.

Biocompatible fluorinated poly(2-hydroxypropenimine)s for safe and efficient gene transfection

The development of non-viral gene delivery systems often requires balancing transfection efficiency and cytotoxicity, particularly when using cationic polymers. Poly(2-hydroxypropenimine) (PHP), with its hydroxyl groups, presents a more biocompatible alternative to traditional polymers such as polyethyleneimine (PEI). In this study, we explored the potential to enhance PHP’s transfection capabilities and reduce its cytotoxicity through a targeted fluorination strategy. Specifically, fluorinated alkyl groups were grafted onto PHP via an ethylene oxide ring-opening reaction, with the reaction conditions optimized for temperature, solvent, and time to ensure efficiency. Transfection experiments using HEK 293 cells demonstrated that fluorinated PHP variants, especially PHP-FH816, significantly improved transfection efficiency, achieving a 75.1 % gene expression rate at an N/P ratio of 2, compared to 44.0 % for unmodified PHP. The transfection experiments in Hela cells also showed substantial transfection efficiency. The gene expression rate was 53.2 % at an N/P ratio of 2 compared to 31.6 % for unmodified PHP. Notably, the fluorinated polymers exhibited lower cytotoxicity and increased serum stability, which suggests their potential as safer gene delivery systems. This study carefully evaluates the feasibility of using fluorinated cationic polymers as next-generation gene delivery vectors, balancing efficacy and safety. It underscores the strategic application of fluorination technology in developing modified polymer vectors that could lead to more efficient and safer non-viral gene therapy solutions.

Optical imaging and gene transfection potential of linear polyethylenimine-coated Ag2S near-infrared quantum dots.

The application of biocompatible heavy metal-free and cationic Ag2S NIR quantum dots (QDs), which have intense luminosity in the 700-900 nm medical range, as a nonviral gene delivery system paves the way to overcome autofluorescence and easily track the delivery of genes in real time. The newly developed small and colloidally stable 2-mercaptopropionic acid (MPA)-capped Ag2S aqueous quantum dots electrostatically complexed with linear polyethyleneimine (Ag2S@2MPA/LPEI) were investigated for the first time both as a strong fluorescent probe and as a vector for nonviral gene delivery for the highest tracking of the system and delivery of genes into the nuclei of different cancer cells. The synthesized Ag2S@2MPA/LPEI quantum dots demonstrated strong optical imaging properties and were used to deliver a green fluorescent protein (GFP) plasmid as a standard gene. For Ag2S@2MPA/LPEI-pDNA nanoparticles, an N/P ratio of 20 was the ideal transfection efficiency. Ag2S@2MPA/LPEI was substantially more compatible with HEK 293T cells than the free 25-kDa linear polyethylenimine (LPEI). Next, the transfection efficiency evaluation of pGFP genes with synthesized Ag2S@2MPA/LPEI and LPEI in different cancer cells demonstrated their high potential as a theranostic cancer gene delivery system. This is the first instance of gene transfection and optical imaging carried out in vitro using Ag2S@2MPA/LPEI QDs. Overall, the newly synthesized highly biocompatible and trackable Ag2S@2MPA/LPEI QDs can be an effective and biocompatible theranostic system for cancer gene therapy.

Enhanced Oncolytic Potential of Engineered Newcastle Disease Virus Lasota Strain through Modification of Its F Protein Cleavage Site.

Newcastle disease virus (NDV) is an oncolytic virus whose F protein cleavage activity is associated with viral infectivity. To explore the potential of modifying F protein cleavage activity to enhance antitumor effects, we constructed a recombinant NDV LaSota strain by replacing its F protein cleavage site with that from the mesogenic Beaudette C (BC) strain using reverse genetics techniques. The resulting virus, rLaSota-BC-RFP, demonstrated significantly enhanced infectivity and tumor cell suppression on the murine melanoma B16F10 cell, characterized by higher cytotoxicity and increased apoptosis compared to its parental strain, rLaSota-RFP. In vivo, rLaSota-BC-RFP treatment of B16F10 tumors in C57BL/6 mice resulted in significant tumor growth inhibition, improved survival rate, and induction of tumor-specific apoptosis and necrosis. Additionally, the rLaSota-BC-RFP treatment enhanced immunostimulatory effects within the tumor microenvironment (TME), characterized by increased infiltration of CD4+ and CD8+ T cells and elevated levels of antitumor immune modulator cytokines, including mouse IL-12, IFN-γ, IL-15, and TNF-α, in the rLaSota-BC-RFP-treated tumor tissues. Collectively, these findings demonstrate that the mesogenic F protein cleavage site enhances the oncolytic potential of the NDV LaSota strain, suggesting that rLaSota-BC-RFP is a promising oncolytic viral vector for gene delivery in cancer immunotherapy.

Immune Modulation Strategies in Gene Therapy: Overcoming Immune Barriers and Enhancing Efficacy.

The immune system presents significant obstacles to gene therapy, which has limited its use in treating many illnesses. New approaches are needed to overcome these problems and improve the effectiveness of gene therapy. This study explores several techniques to immune regulation within gene therapy, a cutting-edge discipline that aims to optimise results by fine-tuning the immune response. We cover new ways to control the immune system and deliver therapeutic genes just where they are needed, including influencing immunological checkpoints, causing immunotolerance, and making smart use of immunomodulatory drugs. In addition, the study provides insight into new developments in the design of less immunogenic gene delivery vectors, which allow for the extension of transgene expression with minimal adverse immune reactions. In order to maximise the efficacy of gene-based therapies, this review analyses these novel approaches and gives a thorough overview of the present state of the art by addressing obstacles and pointing the way toward future developments in immune regulation. Not only does their integration provide new opportunities for the creation of safer and more effective gene treatments, but it also contains the key to overcome current obstacles.

Development and validation of a droplet digital PCR method for quantifying lentiviral vector infectious titer

Lentiviruses, with their high transduction efficiency and gene expression levels, are widely used as gene delivery vectors in the development of chimeric antigen receptor T cells (CAR-T) and other genetically modified cell therapies. Accurate determination of the lentiviral vector infectious titer is essential to ensure effective transduction and product consistency. In this study, we developed an efficient method for lentiviral vector titration based on digital droplet polymerase chain reaction (ddPCR) technology, enabling absolute quantification of the target gene. Benzonase treatment of non-transduced plasmids substantially shortened the experimental period, reducing cell culture duration from 10-14 days–3 days. The method was rigorously validated by assessing specificity, working range, limit of quantification, precision, accuracy, and robustness. This study demonstrates the feasibility of combining enzymatic digestion with ddPCR to quantify lentiviral vector infectious titer and provides a detailed and readily adaptable methodology for the scientific community.

Assessment of Adipocyte Transduction Using Different AAV Capsid Variants.

Adeno-associated viruses (AAVs) are widely used as viral vectors for gene delivery in mammalian cells. We focused on the efficacy of the transduction of AAV2/5, 2/6, 2/8 and 2/9 expressing GFP in preadipocyte cells by live imaging microscopy using IncuCyte S3 and flow cytometry. Three transduction modes in 3T3-L1 preadipocyte cells assessed: AAV transduction in 3T3-L1 preadipocyte cells, transduction with further differentiation into mature adipocyte-like cells and the transduction of differentiated 3T3-L1 adipocytes. For the in vivo study, we injected AAV2/6, AAV2/8 and AAV2/9 in adipose tissue of C57BL6 mice, and the transduction capacity of AAV2/6, along with AAV2/8 and AAV2/9 was evaluated. AAV2/6 demonstrated the highest transduction efficiency in 3T3-L1 preadipocytes, as it was 1.5-2-fold more effective than AAV2/5, and AAV2/8 in the range of viral concentrations from 2 × 104 to 1.6 × 105 VG/cell. AAV2/5 and AAV2/8 showed transduction efficiencies similar to each other. The expression of GFP under the CMV promoter remained stable for up to 20 days. The induction of 3T3-L1 differentiation in three days after AAV transduction did not alter the GFP expression level, and AAV2/6 showed the best transduction efficiency. AAV2/6 demonstrated the ability to transduce mature adipocytes. These results were confirmed by in vivo studies on C57BL6 mice. AAV2/6 had the highest transducing activity on both inguinal and interscapular adipose tissue. Thus, AAV2/6 has demonstrated higher transduction efficacy compared to AAV2/5, AAV2/8 and AAV2/9 both in 3T3-L1 adipocytes and adipose tissue in vivo, which proves its usability along with AAV2/8 and AAV2/9 for gene delivery to adipocytes.

Polymers as Efficient Non-Viral Gene Delivery Vectors: The Role of the Chemical and Physical Architecture of Macromolecules.

Gene therapy is the technique of inserting foreign genetic elements into host cells to achieve a therapeutic effect. Although gene therapy was initially formulated as a potential remedy for specific genetic problems, it currently offers solutions for many diseases with varying inheritance patterns and acquired diseases. There are two major groups of vectors for gene therapy: viral vector gene therapy and non-viral vector gene therapy. This review examines the role of a macromolecule's chemical and physical architecture in non-viral gene delivery, including their design and synthesis. Polymers can boost circulation, improve delivery, and control cargo release through various methods. The prominent examples discussed include poly-L-lysine, polyethyleneimine, comb polymers, brush polymers, and star polymers, as well as hydrogels and natural polymers and their modifications. While significant progress has been made, challenges still exist in gene stabilization, targeting specificity, and cellular uptake. Overcoming cytotoxicity, improving delivery efficiency, and utilizing natural polymers and hybrid systems are vital factors for prospects. This comprehensive review provides an illuminating overview of the field, guiding the way toward innovative non-viral-based gene delivery solutions.

A nanobody interaction with SARS-COV-2 Spike allows the versatile targeting of lentivirus vectors.

While investigating methods to target gene delivery vectors to specific cell types, we examined the potential of using a nanobody against the SARS-CoV-2 Spike protein receptor-binding domain to direct lentivirus infection of Spike-expressing cells. Using four different approaches, we found that lentiviruses with surface-exposed nanobody domains selectively infect Spike-expressing cells. Targeting is dependent on the fusion function of the Spike protein, and conforms to a model in which nanobody binding to the Spike protein triggers the Spike fusion machinery. The nanobody-Spike interaction also is capable of directing cell-cell fusion and the selective infection of nanobody-expressing cells by Spike-pseudotyped lentivirus vectors. Significantly, cells infected with SARS-CoV-2 are efficiently and selectively infected by lentivirus vectors pseudotyped with a chimeric nanobody protein. Our results suggest that cells infected by any virus that forms syncytia may be targeted for gene delivery by using an appropriate nanobody or virus receptor mimic. Vectors modified in this fashion may prove useful in the delivery of immunomodulators to infected foci to mitigate the effects of viral infections.IMPORTANCEWe have discovered that lentiviruses decorated on their surfaces with a nanobody against the SARS-CoV-2 Spike protein selectively infect Spike-expressing cells. Infection is dependent on the specificity of the nanobody and the fusion function of the Spike protein and conforms to a reverse fusion model, in which nanobody binding to Spike triggers the Spike fusion machinery. The nanobody-Spike interaction also can drive cell-cell fusion and infection of nanobody-expressing cells with viruses carrying the Spike protein. Importantly, cells infected with SARS-CoV-2 are selectively infected with nanobody-decorated lentiviruses. These results suggest that cells infected by any virus that expresses an active receptor-binding fusion protein may be targeted by vectors for delivery of cargoes to mitigate infections.

A Comprehensive Review on Phage Therapy and Phage-Based Drug Development.

Phage therapy, the use of bacteriophages (phages) to treat bacterial infections, is regaining momentum as a promising weapon against the rising threat of multidrug-resistant (MDR) bacteria. This comprehensive review explores the historical context, the modern resurgence of phage therapy, and phage-facilitated advancements in medical and technological fields. It details the mechanisms of action and applications of phages in treating MDR bacterial infections, particularly those associated with biofilms and intracellular pathogens. The review further highlights innovative uses of phages in vaccine development, cancer therapy, and as gene delivery vectors. Despite its targeted and efficient approach, phage therapy faces challenges related to phage stability, immune response, and regulatory approval. By examining these areas in detail, this review underscores the immense potential and remaining hurdles in integrating phage-based therapies into modern medical practices.

Temperature Sensitive PNIPAm-g-PEI/Gold Nanotriangle for Gene Delivery Promotion.

As a two-dimensional material, gold nanotriangles (GNTs) are rarely studied in the field of gene delivery. In this study, a temperature-responsive GNTs was developed as a novel carrier for gene delivery. The temperature-sensitive copolymer PNIPAm-g-PEI was grafted onto the surface of GNTs to construct a PNIPAm-g-PEI/GNTs composite controllable release platform. The lower critical solution temperature (LCST) of PNIPAm-g-PEI/GNTs was found to be 42°C, and the particle size of PNIPAm-g-PEI/GNTs was 150nm at this temperature. Gel electrophoresis experiments showed that PNIPAm-g-PEI/GNTs completely condensed DNA at 20μg/mL, and PNIPAm-g-PEI/GNTs promoted the release of DNA under laser irradiation. Luciferase and green fluorescent protein reporter gene assays demonstrated that the transfection efficiency of PNIPAm-g-PEI/GNTs was 1.5 and 7.2 times that of PEI, respectively. These results demonstrated the promising potential of temperature-responsive GNTs as effective and safe gene delivery vectors.

Potential applications of PEI loaded graphene oxide quantum dots in safe and efficient DNA delivery

In order to improve the safety and efficacy of gene delivery using polyethyleneimine (PEI), this work focused on developing PEI quantum dots and incorporating them onto graphene to improve gene loading capacity. The successful creation of graphene-polyethyleneimine quantum dots (GPQDs) was confirmed through fluorescence emission spectrum and infrared spectroscopy. Both polyethyleneimine quantum dots (PQDs) and GPQDs exhibited blue fluorescence when excited between 310 and 430 nm, indicating that they retained the fluorescence characteristics of broad excitation and narrow emission. Furthermore, GPQDs displayed smaller particle sizes, increased hydrophilicity, and better dispersibility compared to PQDs. GPQDs were able to efficiently load DNA with lower cytotoxicity than PQDs and PEI. The enhanced fluorescence properties of GPQDs allowed for the observation that GPQDs/DNA complexes were effectively internalized by cells with higher uptake efficiency than PEI/DNA and PQDs/DNA complexes. The study demonstrated that GPQDs/DNA complexes successfully transfected 293T and HeLa cells, with GPQDs prepared using PEI25k showing improved cell uptake and transfection efficiency compared to those prepared with PEI10k. Overall, the findings suggest that GPQDs are a more effective and safer gene delivery vector than PEI, with promising potential for future gene delivery applications.